证券代码：688617 证券简称：惠泰医疗 公告编号：2026-007

Group 1 - The company reported a revenue of 258,392.73 million RMB for the reporting period, representing a growth of 25.08% compared to the same period last year [3] - The net profit attributable to the parent company's owners was 82,063.66 million RMB, an increase of 21.91% year-on-year [3] - The net profit after deducting non-recurring gains and losses was 79,087.59 million RMB, reflecting a growth of 23.00% compared to the previous year [3] - The total assets at the end of the reporting period amounted to 365,185.66 million RMB, which is a 22.52% increase from the beginning of the reporting period [3] Group 2 - The company implemented a capital reserve conversion plan during the reporting period, resulting in a 44.80% increase in share capital, with a distribution of 4.5 shares for every 10 shares held [4] - The growth in operating performance was attributed to continuous market expansion efforts, effective marketing activities, and a focus on core products such as PFA [3] - The company emphasized cost control, directing R&D and sales expenses towards market promotion and clinical validation of core products, optimizing expenditure structure and achieving synchronized growth in net profit and revenue [3]